Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Oltipraz (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Registrational; Therapeutic Use
- Sponsors PharmaKing
- 29 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov
- 28 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.